The standard of care for jail management of opioid use disorder (OUD) is to offer Medications for Opioid Use Disorder (MOUD/MAT) to individuals upon admission and, if accepted, to continue it during their incarceration. All 3 FDA-approved medications (methadone, buprenorphine, and naltrexone) should be available. An injectable form of buprenorphine (Sublocade®) that only needs to be administered once a month is now available in the US. In some jails it has proven to be a very valuable addition to the other available MOUD medications they have in their medication toolbox. In this presentation, administrators from 2 jails in different states will share their experience using long-acting buprenorphine, focusing on the benefits from a custody perspective as well as drawbacks and lessons learned.
Learning Objectives:
Understand what long-acting buprenorphine is and how it differs from other opioid use disorder medications
Understand the advantages and disadvantages of including Sublocade in a jail's MOUD/MAT program
Understand how to go about adding Sublocade to the MOUD/MAT program
